3-tetrahydro[2]furyl-propionic acid amide | 98435-68-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-tetrahydro[2]furyl-propionic acid amide
• 英文别名: 3-Tetrahydro[2]furyl-propionsaeure-amid；Tetrahydro-furan-2-ylmethyl-acetamide；3-(oxolan-2-yl)propanamide
• CAS: 98435-68-8
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: KFZKNFSJFKMJQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-tetrahydro[2]furyl-propionic acid amide 、 2-酮丁酸 以 甲苯 为溶剂， 以19%的产率得到(Z)-2-[3-(oxolan-2-yl)propanoylamino]but-2-enoic acid
  参考文献：
  名称：

  Inhibition of the mammalian .beta.-lactamase renal dipeptidase (dehydropeptidase-I) by Z-2-(acylamino)-3-substituted-propenoic acids

  摘要：

  The title enzyme deactivates the potent carbapenem antibiotic imipenem in the kidney, producing low antibiotic levels in the urinary tract. A series of (Z)-2-(acylamino)-3-substituted-propenoic acids (3) are specific, competitive inhibitors of the enzyme capable of increasing the urinary concentration of imipenem in vivo. Many of the compounds were prepared in one step from an alpha-keto acid and a primary amide. The optimum R2 groups are 2,2-dimethyl, -dichloro, and -dibromocyclopropyl. With R2 = 2,2-dimethylcyclopropyl (DMCP), a wide variety of R3 groups including alkyl, oxa- and thiaalkyl, and alkyl groups containing acidic, basic, and neutral substituents give effective inhibitors with Ki values of 0.02-1 microM and a range of pharmacokinetic properties. By resolution of enantiomers and X-ray crystallography, the enzyme-inhibitory activity of the DMCP group was found to reside with the 1S isomer. The cysteinyl compound 176 (cilastatin, MK-0791) has the desired pharmacological properties and has been chosen for combination with imipenem.

  DOI：

  10.1021/jm00389a018
• 作为产物：
  描述：

  5-furfurylidenerhodanine 在 甲醇 、 镍 作用下， 生成 3-tetrahydro[2]furyl-propionic acid amide
  参考文献：
  名称：

  Behringer et al., Chemische Berichte, 1958, vol. 91, p. 2773,2783

  摘要：

  DOI：

文献信息

• [EN] NOVEL 1,3,8-TRIAZASPIRO[4.5]DECANONES WITH HIGH AFFINITY FOR OPIOID RECEPTOR SUBTYPES<br/>[FR] NOUVELLES 1,3,8-TRIAZASPIRO[4.5]DECANONES POSSEDANT UNE AFFINITE ELEVEE POUR LES SOUS-TYPES DU RECEPTEUR OPIOIDE
  申请人：NOVO NORDISK A/S

  公开号：WO1999059997A1

  公开（公告）日：1999-11-25

  (EN) The present invention relates to use of small organic compounds acting as opioid receptor ligands for the treatment of vasomotor disturbances. In particular the present invention relates to the triazaspiro compounds of general formula (Ia) or (Ib) wherein R1 is selected among phenyl, arylalkyl or thienyl; R2 is selected among aminophenyl, C1-6-monoalkylaminophenyl, C1-6-dialkylaminophenyl, cyanophenyl, C2-6-alkylphenyl, naphthyl, tetrahydronaphthyl, furanyl, indanyl, benzothienyl or benzofuranyl; R3 is hydrogen, C1-6-alkyl, phenyl, benzyl, or acetyl; R4 is hydrogen or (CH2)m-(CHR9)-(CH2)p-AR11; R5 is hydrogen or C1-4-alkyl; z is CHR10 wherein R10 is hydrogen, C1-6-alkyl, phenyl or arylalkyl - or z is C2-8-alkylene, C2-8-alkenylene or C2-8-alkynylene; n is 1 or 2; or a pharmaceutically acceptable salt thereof for the treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes.(FR) L'invention concerne l'utilisation de petits composés organiques agissant comme des ligands du récepteur opioïde, pour le traitement de troubles vasomoteurs. Elle se rapporte notamment à des composés triaza-spiro de formule générale (Ia) ou (Ib), dans lesquelles R1 est choisi parmi phényle, arylalkyle ou thiényle; R2 est choisi parmi aminophényle, monoalkylaminophényle C1-6, dialkylaminophényle C1-6, cyanophényle, alkylphénylenaphtyle C2-6, tétrahydronaphtyle, furanyle, indanyle, benzothiényle ou benzofuranyle; R3 représente hydrogène, alkyle C1-6, phényle, benzyle ou acétyle; R4 représente hydrogène ou (CH2)m-(CHR9)-(CH2)p-AR11; R5 représente hydrogène ou alkyle C1-4; z représente CHR10, R10 représentant hydrogène, alkyle C1-6, phényle ou arylalkyle - ou z représente alkylène C2-8, alcénylène C2-8 ou alkynylène C2-8; n vaut 1 ou 2. Elle peut encore se rapporter à un sel acceptable au plan pharmaceutique desdits composés, ledit sel et les composés étant utilisés pour le traitement de la migraine, du diabète non-insulinodépendant (diabète de type II), la septicémie, l'inflammation, l'incontinence et/ou les troubles vasomoteurs, notamment les effets vasomoteurs périphériques connus sous le nom de bouffées de chaleur.

  本发明涉及使用作为阿片受体配体的小有机化合物治疗血管运动失调。特别是本发明涉及一般式（Ia）或（Ib）的三唑螺化合物，其中R1在苯基，芳基烷基或噻吩基中选择；R2在氨基苯基，C1-6-单烷基氨基苯基，C1-6-双烷基氨基苯基，氰基苯基，C2-6-烷基苯基，萘基，四氢萘基，呋喃基，茚基，苯并噻吩基或苯并呋喃基中选择；R3是氢，C1-6-烷基，苯基，苄基或乙酰基；R4是氢或（CH2）m-（CHR9）-（CH2）p-AR11；R5是氢或C1-4-烷基；z是CHR10，其中R10是氢，C1-6-烷基，苯基或芳基烷基-或z是C2-8-烷基，C2-8-烯基或C2-8-炔基；n为1或2；或其药学上可接受的盐，用于治疗偏头痛，非胰岛素依赖性糖尿病（2型糖尿病），败血症，炎症，失禁和/或血管运动失调，特别是被称为潮热或热潮的周围血管运动效应。
• Amide compounds and methods of using the same
  申请人：Thompsom K Scott

  公开号：US20050107444A1

  公开（公告）日：2005-05-19

  Disclosed is a compound having the formula pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.

  本发明公开了一种具有以下结构式的化合物，其药学上可接受的盐或溶剂合物以及含有它们的药物组合物，其中结构变量如本文所定义。本发明的化合物、盐和溶剂合物可用作LXR激动剂。
• Tie-2 modulators and methods of use
  申请人：Chen Jeff

  公开号：US20060293342A1

  公开（公告）日：2006-12-28

  The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.

  本发明提供了用于调节蛋白激酶酶活性以调节细胞活动（如增殖、分化、程序性细胞死亡、迁移和化学侵袭）的化合物。本发明的化合物抑制、调节和/或调节激酶，特别是Tie-2。使用这些化合物和它们的药物组合物治疗激酶依赖性疾病和病况的方法也是本发明的一个方面。
• FUSED RING HETEROCYCLE KINASE MODULATORS
  申请人：Chen Chixu

  公开号：US20080261921A1

  公开（公告）日：2008-10-23

  The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.

  本发明提供了融合环杂环化合物作为激酶调节剂，包含这些调节剂的药物组合物，以及使用这些调节剂治疗由激酶活性介导的疾病的方法。
• Fused ring heterocycle kinase modulators
  申请人：SGX Pharmaceuticals, Inc.

  公开号：US08242280B2

  公开（公告）日：2012-08-14

  The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.

  本发明提供了融合环杂环作为激酶调节剂，包含这些调节剂的制药组合物，以及使用这些调节剂治疗由激酶活性介导的疾病的方法。